HC Wainwright Estimates FibroBiologics Q1 Earnings

FibroBiologics, Inc. (NASDAQ:FBLG) – HC Wainwright issued their Q1 2025 EPS estimates for shares of FibroBiologics in a research note issued to investors on Tuesday, April 1st. HC Wainwright analyst M. Caufield forecasts that the company will earn ($0.11) per share for the quarter. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for FibroBiologics’ current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for FibroBiologics’ Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS and FY2029 earnings at ($0.59) EPS.

Other research analysts also recently issued research reports about the company. D. Boral Capital restated a “buy” rating and issued a $16.00 target price on shares of FibroBiologics in a research note on Tuesday. Rodman & Renshaw initiated coverage on FibroBiologics in a report on Thursday, December 12th. They set a “buy” rating and a $12.00 price target for the company. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, FibroBiologics has an average rating of “Buy” and a consensus price target of $13.00.

FibroBiologics Stock Performance

FibroBiologics stock opened at $0.86 on Wednesday. FibroBiologics has a 12 month low of $0.86 and a 12 month high of $13.59. The company’s fifty day simple moving average is $1.28 and its 200-day simple moving average is $2.14.

Hedge Funds Weigh In On FibroBiologics

Several hedge funds have recently bought and sold shares of FBLG. Charles Schwab Investment Management Inc. lifted its position in shares of FibroBiologics by 5.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 69,732 shares of the company’s stock worth $215,000 after buying an additional 3,451 shares during the last quarter. The Manufacturers Life Insurance Company bought a new stake in FibroBiologics during the third quarter worth approximately $32,000. Jane Street Group LLC bought a new stake in FibroBiologics during the third quarter worth approximately $37,000. Intech Investment Management LLC acquired a new position in FibroBiologics during the fourth quarter valued at approximately $25,000. Finally, Virtu Financial LLC bought a new position in shares of FibroBiologics in the fourth quarter valued at approximately $30,000.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.